Navigation Links
OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
Date:8/21/2014

NEW YORK, Aug. 21, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, on its approval to list on The NASDAQ Capital Market.  Immune previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

"We congratulate Immune Pharmaceuticals on the successful execution of its growth strategy and achievement of this important milestone," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "OTCQX has provided its investors with an efficient, transparent and information-rich trading market so they can easily analyze, value and trade its securities.  We are proud to have helped contribute to Immune's success as a public company as it takes this next step."     

"Immune Pharma went public one year ago and started trading on OTCQX.  Over the past six months, we have significantly increased our daily trading volume and raised capital to prepare for execution on our clinical milestones and for up-listing.  On Thursday, August 21, 2014, we will begin trading on The Nasdaq Capital Market, enabling additional investors to participate in our story," said Dr. Daniel Teper, CEO of Immune.

OTCQX is the marketplace of choice for U.S. and global companies that are looking to execute their business plans and graduate to a U.S. stock exchange listing.  Immune is the sixth OTCQX company to graduate to the NYSE MKT or NASDAQ markets this year.  Others include: BioPath Holdings Inc., Cellectar Biosciences Inc., Gulf Coast Ultra Deep Loyalty Trust, RXI Pharmaceuticals Corp. and Sphere 3D Corp.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed


'/>"/>
SOURCE OTC Markets Group Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular Diagnostics Markets
2. Microarray Markets - 2013 Report Examines Companies that are Actively Developing and Marketing Microarray Instrumentation or Microarray Biochips
3. Stem Cell Markets - 2013 Report Examines the Use of Stem Cells in Developing New Therapies for Disease
4. BCC Research Publishes a New Report On Global Markets for Flow Cytometry
5. Globalizing Clinical Trials to Include Emerging Markets, New Life Science Webinar Hosted by Xtalks
6. BCC Research Publishes a New Report on Global Markets for Biochips
7. BCC Research Publishes a New Report On Global Markets for Rnai Technologies
8. Interventional Cardiology Devices - Emerging Markets 2009-2015
9. IDC MarketScape annovera la soluzione cloud-based di Veeva tra le principali soluzioni CRM dedicate alle scienze della vita
10. IDC MarketScape Named Cloud-based Veeva a Leader in Life Sciences CRM
11. Point of Care Diagnostic Testing: World Markets Report 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
Breaking Biology News(10 mins):